iCAD is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to identify cancer and life-threatening conditions earlier by making medical services more effective, more accessible and more affordable for patients worldwide. In December of 2003, iCAD merged with and acquired CADx Systems, Inc. and its parent company Qualia Computing, Inc., bringing together two of the three companies approved by the US Food and Drug Administration (FDA) to market CAD systems for the detection of breast cancer in the United States. Headquartered in Nashua, New Hampshire, our common stock is listed on the NASDAQ Stock Market under the symbol "ICAD".
For investor relations, please contact:
Kevin McGrath
Cameron Associates
+1 212 245 4577 phone
kevin@cameronassoc.com
© 2006 iCAD, Inc. All rights reserved.
